FocalTherics Launches First Commercial Endometriosis Program in Europe, Treating Initial Patients
FOCL has more than doubled off its 52-week low of $1.21.
Summary
FocalTherics (EDAP TMS SA) successfully launched its first commercial Focal One program for deep infiltrating endometriosis in Europe, with initial patients treated at Toulouse University Hospital. This expands the market for their Focal One Robotic HIFU system into a new, significant indication, addressing an unmet need for a non-surgical treatment option for millions of women globally. The company is actively training over 10 hospitals across Europe, the UK, and Latin America, signaling a broader rollout and potential for substantial revenue growth from this new application.
At the time of this announcement, FOCL was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.8M. The 52-week trading range was $1.21 to $5.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.